OR WAIT null SECS
November 20, 2025
Video
Bhatt discusses the positive results from the phase 2 trial of quarterly and monthly doses of investigational IL-6 inhibitor pacibekitug.
November 13, 2025
Podcast
Discover groundbreaking insights from ASN Kidney Week on the SURPASS-CVOT trial.
November 12, 2025
Weir pointed out that significant benefits were seen with concurrent SGLT2 inhibitor use.
November 08, 2025
Discover groundbreaking findings from the FINE-ONE trial on finerenone, offering hope for type 1 diabetes patients with CKD.
Discover groundbreaking insights on SGLT2 inhibitors and their impact on kidney health, cardiovascular outcomes, and patient care at ASN Kidney Week.
Article
New research shows nearly all adults with hypertensive chronic kidney disease benefit from a
November 07, 2025
SGLT2 inhibitors show significant kidney protection for chronic kidney disease regardless of diabetes status or albumin levels.
November 06, 2025
Findings showed anxiety, depression, and sleep disorders were highly prevalent among ESRD patients undergoing maintenance hemodialysis
Finerenone significantly reduces UACR in type 1 diabetes patients with chronic kidney disease, offering new hope for treatment.
November 03, 2025
Kidney Week 2025 showcases groundbreaking clinical trials and FDA approvals, marking a transformative era in nephrology and kidney disease treatment.
